Jessica L Cindass
Overview
Explore the profile of Jessica L Cindass including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
70
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Decar S, Carpenter E, Adams A, Chick R, Clifton G, Stojadinovic A, et al.
Cancer Treat Res Commun
. 2024 Sep;
41:100843.
PMID: 39305541
Background: The autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine is produced from dendritic cells (DC) loaded ex vivo with autologous tumor lysate (TL). TLPLDC has been shown to decrease...
2.
OShea A, Valdera F, Ensley D, Smolinsky T, Cindass J, Kemp Bohan P, et al.
Clin Immunol
. 2022 Aug;
245:109095.
PMID: 35973640
Rapamycin inhibits the mechanistic (formally mammalian) target of rapamycin (mTOR), an evolutionarily conserved intracellular kinase that influences activation of growth signaling pathways and immune responses to malignancy. Rapamycin has been...
3.
Chick R, Faries M, Hale D, Kemp Bohan P, Hickerson A, Vreeland T, et al.
Cancer Med
. 2021 May;
10(13):4302-4311.
PMID: 33982452
Background: Checkpoint inhibitors (CPI) in combination with cell-based vaccines may produce synergistic antitumor immunity. The primary analysis of the randomized and blinded phase IIb trial in resected stage III/IV melanoma...
4.
Vreeland T, Clifton G, Hale D, Chick R, Hickerson A, Cindass J, et al.
Ann Surg Oncol
. 2021 Feb;
28(11):6126-6137.
PMID: 33641012
Background: Melanoma therapy has changed dramatically over the last decade with improvements in immunotherapy, yet many patients do not respond to current therapies. This novel vaccine strategy may prime a...
5.
Kemp Bohan P, Chick R, OShea A, Vreeland T, Hickerson A, Cindass J, et al.
Cancer Prev Res (Phila)
. 2021 Jan;
14(5):551-562.
PMID: 33514567
No approved medical therapies prevent progression of low-grade prostate cancer. Rapamycin inhibits cell proliferation and augments immune responses, producing an antitumor effect. Encapsulated rapamycin (eRapa) incorporates rapamycin into a pH-sensitive...
6.
Kemp Bohan P, Chick R, Hickerson A, Messersmith L, Williams G, Cindass J, et al.
Cancer Immunol Immunother
. 2020 Nov;
70(5):1465-1474.
PMID: 33180182
Background: Colorectal cancer (CRC) tumor microenvironment (TME) characteristics, such as tumor infiltrating lymphocyte (TIL) densities and PD-L1 status, are predictive of recurrence, disease-free survival, and overall survival. In many malignancies,...
7.
Kemp Bohan P, Mankaney G, Vreeland T, Chick R, Hale D, Cindass J, et al.
Fam Cancer
. 2020 Jun;
20(1):23-33.
PMID: 32507936
Familial adenomatous polyposis (FAP) is a hereditary colorectal cancer syndrome characterized by colorectal adenomas and a near 100% lifetime risk of colorectal cancer (CRC). Prophylactic colectomy, usually by age 40,...